Shire’s Vyvanse demonstrates efficacy in new trial

Shire has published data from a phase IIIb study of its attention deficit hyperactivity disorder (ADHD) drug Vyvanse, demonstrating its efficacy among adult patients.

Results published in the medical journal Behavioral and Brain Functions showed that patients using the once-daily Vyvanse Capsule CII treatment benefited from improved attention spans between two and 14 hours after administering.

It has previously been proven to offer similar benefits among children aged between six and 12 in previous clinical studies.

Dr Matthew Brams, study author and clinical assistant professor of psychiatry at Baylor College of Medicine, said this illustrates the drug’s benefits for ADHD sufferers wishing to manage their symptoms during a working day.

He added: “Because ADHD symptoms may extend into the evening for many adults, the availability of treatments that provide symptom improvement throughout the day is important.”

Earlier this month, the company published phase III trial data for the hereditary angioedema Firazyr, illustrating its efficacy when compared to placebo.